[go: up one dir, main page]

BR9706142A - Compostos substituídos por sulfonamida processos para a sua preparação seu emprego como medicamento ou diagnóstico e os preparados farmacêuticos contendo os mesmos - Google Patents

Compostos substituídos por sulfonamida processos para a sua preparação seu emprego como medicamento ou diagnóstico e os preparados farmacêuticos contendo os mesmos

Info

Publication number
BR9706142A
BR9706142A BR9706142A BR9706142A BR9706142A BR 9706142 A BR9706142 A BR 9706142A BR 9706142 A BR9706142 A BR 9706142A BR 9706142 A BR9706142 A BR 9706142A BR 9706142 A BR9706142 A BR 9706142A
Authority
BR
Brazil
Prior art keywords
nme2
ome
nhso2me
so2me
so2nh2
Prior art date
Application number
BR9706142A
Other languages
English (en)
Inventor
Joachim Brendel
Hans Jochen Lang
Uwe Gerlach
Klaus Weidmann
Original Assignee
Hoechst Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE1996152213 external-priority patent/DE19652213A1/de
Priority claimed from DE1997130326 external-priority patent/DE19730326A1/de
Application filed by Hoechst Ag filed Critical Hoechst Ag
Publication of BR9706142A publication Critical patent/BR9706142A/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38Nitrogen atoms
    • C07D215/42Nitrogen atoms attached in position 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72Quinazolines; Hydrogenated quinazolines
    • C07D239/86Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94Nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D265/00Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/041,3-Oxazines; Hydrogenated 1,3-oxazines
    • C07D265/121,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
    • C07D265/141,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D265/161,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with only hydrogen or carbon atoms directly attached in positions 2 and 4

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Indole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Quinoline Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cephalosporin Compounds (AREA)
BR9706142A 1996-12-16 1997-12-15 Compostos substituídos por sulfonamida processos para a sua preparação seu emprego como medicamento ou diagnóstico e os preparados farmacêuticos contendo os mesmos BR9706142A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE1996152213 DE19652213A1 (de) 1996-12-16 1996-12-16 Sulfonamid-substituierte Verbindungen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE1997130326 DE19730326A1 (de) 1997-07-15 1997-07-15 Sulfonamid-substituierte Verbindungen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltende pharmazeutische Zubereitungen

Publications (1)

Publication Number Publication Date
BR9706142A true BR9706142A (pt) 1999-05-18

Family

ID=26032247

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9706142A BR9706142A (pt) 1996-12-16 1997-12-15 Compostos substituídos por sulfonamida processos para a sua preparação seu emprego como medicamento ou diagnóstico e os preparados farmacêuticos contendo os mesmos

Country Status (24)

Country Link
US (1) US5856338A (pt)
EP (1) EP0847996B1 (pt)
JP (1) JP4317601B2 (pt)
KR (1) KR19980064151A (pt)
CN (1) CN1185435A (pt)
AT (1) ATE234821T1 (pt)
AU (1) AU725699B2 (pt)
BR (1) BR9706142A (pt)
CA (1) CA2224885A1 (pt)
CZ (1) CZ403997A3 (pt)
DE (1) DE59709560D1 (pt)
DK (1) DK0847996T3 (pt)
ES (1) ES2195071T3 (pt)
HR (1) HRP970684A2 (pt)
HU (1) HUP9702475A3 (pt)
ID (1) ID19152A (pt)
IL (1) IL122576A0 (pt)
NO (1) NO975887L (pt)
NZ (1) NZ329200A (pt)
PL (1) PL323809A1 (pt)
PT (1) PT847996E (pt)
SI (1) SI0847996T1 (pt)
SK (1) SK171797A3 (pt)
TR (1) TR199701605A2 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9711220D0 (en) * 1997-05-30 1997-07-23 Isis Innovation Antiarrhythmic agents
DE19858253A1 (de) * 1998-12-17 2000-06-21 Aventis Pharma Gmbh Verwendung von Inhibitoren des KQt1-Kanals zur Herstellung eines Medikaments zur Behandlung von Krankheiten, die durch Helminthen und Ektoparasiten hervorgerufen werden
US7183075B2 (en) 2000-04-14 2007-02-27 Vanderbilt University Purified and isolated potassium-chloride cotransporter nucleic acids and polypeptides and therapeutic and screening methods using same
TWI357901B (en) * 2004-03-12 2012-02-11 Lundbeck & Co As H Substituted morpholine and thiomorpholine derivati
CN113402476B (zh) * 2021-06-21 2022-04-19 广东湛江海洋医药研究院 一种亚胺噁嗪衍生物及其制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3737195A1 (de) * 1987-11-03 1989-05-18 Bayer Ag Chromanderivate, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln
GB8808069D0 (en) * 1988-04-07 1988-05-11 Fujisawa Pharmaceutical Co Benzopyran derivatives & processes for preparation thereof
FR2639349B1 (fr) * 1988-11-23 1991-02-22 Sanofi Sa Nouveaux derives du chromane actifs sur le systeme nerveux central, leur procede de preparation et les compositions pharmaceutiques en contenant
US5104890A (en) * 1989-03-28 1992-04-14 Fujisawa Pharmaceutical Company, Ltd. Benzopyran derivatives and processes for preparation thereof
WO1994004521A1 (fr) * 1992-08-17 1994-03-03 Chugai Seiyaku Kabushiki Kaisha Derives de benzopyranne et de benzoxazine
TR199700369A2 (xx) * 1996-05-15 1997-12-21 Hoechst Ag S�lfonamid ile s�bstit�e edilmi� kroman'lar, bunlar�n �retilmesine mahsus usul, ila� veya diyagnostik olarak kullan�lmalar� ve bunlar� i�eren ila�.

Also Published As

Publication number Publication date
AU725699B2 (en) 2000-10-19
CA2224885A1 (en) 1998-06-16
JPH10182610A (ja) 1998-07-07
NO975887D0 (no) 1997-12-15
MX9710126A (es) 1998-07-31
PT847996E (pt) 2003-07-31
CZ403997A3 (cs) 1998-07-15
HU9702475D0 (en) 1998-03-02
SK171797A3 (en) 1998-07-08
DE59709560D1 (de) 2003-04-24
HUP9702475A3 (en) 2000-01-28
EP0847996A1 (de) 1998-06-17
AU4837397A (en) 1998-06-18
HUP9702475A2 (hu) 1999-06-28
SI0847996T1 (en) 2003-08-31
JP4317601B2 (ja) 2009-08-19
CN1185435A (zh) 1998-06-24
EP0847996B1 (de) 2003-03-19
NO975887L (no) 1998-06-17
ATE234821T1 (de) 2003-04-15
US5856338A (en) 1999-01-05
TR199701605A2 (xx) 1998-07-21
KR19980064151A (ko) 1998-10-07
HRP970684A2 (en) 1998-10-31
ES2195071T3 (es) 2003-12-01
DK0847996T3 (da) 2003-06-30
PL323809A1 (en) 1998-06-22
ID19152A (id) 1998-06-18
NZ329200A (en) 1999-05-28
IL122576A0 (en) 1998-06-15

Similar Documents

Publication Publication Date Title
DE3677452D1 (de) Chinazolinderivate, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen.
ES2192394T3 (es) Profarmacos de inhibidores de la bomba de protones.
ATE239680T1 (de) Sulfonamid derivate und deren verwendung
FI831604L (fi) Pyridinderivat, deras framstaellning och anvaendning
DK0579496T3 (da) 4-Aminoquinazolinderivater og deres anvendelse som lægemidler
DK148392D0 (da) Heterocykliske forbindelser
DZ1694A1 (fr) "n-(2-Aminoethyl)-benzothialozones".
KR950700321A (ko) 혈소판 응집 억제제로서의 4-옥소-2-티옥소이미다졸리딘 유도체(4-Oxo-2-thioxoimidazolidine derivatives as inhibitors of blood platelet aggregation)
BR9706142A (pt) Compostos substituídos por sulfonamida processos para a sua preparação seu emprego como medicamento ou diagnóstico e os preparados farmacêuticos contendo os mesmos
PT90912A (pt) Processo para a preparacao de derivados de tiofenol
DK0599240T3 (da) Indol-7-carboxamidderivater som analgetika
AR241182A1 (es) Un procedimiento para preparar n-(2-metoxifenil)-piperazinil-alcanoil anilidas.
ES531063A0 (es) Procedimiento para la preparacion de un nuevo compuesto heterociclico
DE3687675D1 (de) Substituierte toluidine, verfahren zu ihrer herstellung, diese enthaltende pharmazeutische zubereitungen und ihre verwendung als magensaeuresekretionshemmer.
AR015140A1 (es) N-(3,4-dihidro-2h-piran-4-il)sulfonamidas, procedimiento para su preparacion, su utilizacion para la preparacion de un medicamento, un preparadofarmaceutico y medicamento
EA200400666A3 (ru) Новые соединения бензотиазина и бензотиадиазина, способ их получения и фармацевтические композиции, которые их содержат
SE8400628D0 (sv) Mitomycin analogs
ATE117674T1 (de) Sulfonamide enthaltende arzneimittel, neue sulfonamide und verfahren zu ihrer herstellung.
AR013133A1 (es) Un compuesto de metaloceno en puente, un procedimiento para prepararlo, un ligando, un sistema catalizador para la polimerizacion de olefinas, unprocedimiento para la polimerizacion de olefinas, y un procedimiento para la oligomerizacion de olefinas
TH1033A (th) การใช้ไนโตร อะมิโน และเอโรอิลอะมิโน-n- เฟนนิลพิริดีนอะมีนในกรรมวิธีการเตรียมสารพิริโด [1,4] -เบนโซไดอะซิฟินซึพีนต่าง ๆ

Legal Events

Date Code Title Description
FA10 Dismissal: dismissal - article 33 of industrial property law
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]